Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Masanori Okada, Seiichiro Sugimoto, Masaomi Yamane, Shinichiro Miyoshi
No abstract text is available yet for this article.
October 24, 2016: Japanese Journal of Clinical Oncology
Kumiko Saika, Ryoko Machii
No abstract text is available yet for this article.
October 24, 2016: Japanese Journal of Clinical Oncology
Kozo Kataoka, Kenichi Nakamura, Carmela Caballero, Serge Evrard, Anastassia Negrouk, Manabu Shiozawa, Laurence Collette, Haruhiko Fukuda, Denis Lacombe
The demand for international collaboration in cancer clinical trials has grown stronger to maximize efficiency, avoid duplication of effort and to achieve effective implementation of research results into medical practice. Infrastructures that could facilitate intercontinental collaboration not only between Europe and United States  but also between Europe and Asia are urgently needed. The European Organisation for Research and Treatment of Cancer, one of the major cancer clinical research infrastructure in Europe, initiated collaboration with the Japan Clinical Oncology Group, the largest cancer research cooperative group in Japan...
October 20, 2016: Japanese Journal of Clinical Oncology
Keiju Aokage, Junji Yoshida, Tomoyuki Hishida, Masahiro Tsuboi, Hisashi Saji, Morihito Okada, Kenji Suzuki, Syunichi Watanabe, Hisao Asamura
Since 'radical lobectomy' was reported by Cahan in 1960, the standard surgical care for lung cancer has been lobectomy, in which units of the lobe are excised with their specific regional hilar and mediastinal lymphatics. However, pulmonary function-preserving limited resection for lung cancer has gradually become more prevalent in the late 20th century. In 1995, Ginsberg et al. conducted a randomized controlled trial in which limited resection (segmentectomy and wide-wedge resection) and lobectomy for stage I lung cancer were compared and reported that limited resection should not be applied to healthy patients with clinical stage IA lung cancer...
October 20, 2016: Japanese Journal of Clinical Oncology
Keiju Aokage, Morihito Okada, Kenji Suzuki, Shogo Nomura, Shigeki Suzuki, Norifumi Tsubokawa, Takahiro Mimae, Aritoshi Hattori, Tomoyuki Hishida, Junji Yoshida, Masahiro Tsuboi
OBJECTIVE: Exclusion of patients with a history of other cancer treatment except in situ situation has been considered to be inevitable for clinical trials investigating survival outcome. However, there have been few reports confirming these influences on surgical outcome of lung cancer patients ever. METHODS: Multi-institutional, individual data from patients with non-small cell lung cancer resected between 2000 and 2013 were collected. The patients were divided into two groups: those with a history of gastrointestinal tract cancer (GI group) and those without any history (non-GI group)...
October 15, 2016: Japanese Journal of Clinical Oncology
Kei Mizuno, Takahiro Inoue, Hidefumi Kinoshita, Toshifumi Yano, Hiroaki Kawanishi, Hideki Kanda, Naoki Terada, Takashi Kobayashi, Tomomi Kamba, Yoshiki Mikami, Taizo Shiraishi, Yoshiko Uemura, Yukihiro Imai, Gen Honjo, Tomoyuki Shirase, Kazuhiro Okumura, Mutsushi Kawakita, Keiji Ogura, Yoshiki Sugimura, Tadashi Matsuda, Osamu Ogawa
OBJECTIVE: Active surveillance has emerged as an alternative to immediate treatment in men with favorable-risk prostate cancer; however, consensus about defining the appropriate candidates is still lacking. To examine the factors predicting unfavorable pathology among active surveillance candidates, we assessed low-risk radical prostatectomy specimens. METHODS: This retrospective study included 1753 men who had undergone radical prostatectomy at six independent institutions in Japan from 2005 to 2011...
October 15, 2016: Japanese Journal of Clinical Oncology
Kinichi Hotta, Takahisa Matsuda, Yasuo Kakugawa, Hiroaki Ikematsu, Nozomu Kobayashi, Ryoji Kushima, Atsushi Hozawa, Takeshi Nakajima, Taku Sakamoto, Mika Mori, Takahiro Fujii, Yutaka Saito
OBJECTIVE: Colorectal cancer screening program using fecal immunochemical test had been conducted on an isolated island named Nii-jima. However, the participation rate of the program had been approximately 12%, which was lower than average level of Japan. This study aimed to evaluate the participation rate, safety and efficacy of a colorectal cancer screening program using colonoscopy on the island. METHODS: Educational campaigns were actively conducted every month using information bulletins and special propaganda pamphlets...
October 13, 2016: Japanese Journal of Clinical Oncology
Ei-Ichiro Takaoka, Jun Miyazaki, Hitoshi Ishikawa, Koji Kawai, Tomokazu Kimura, Ryutaro Ishitsuka, Takahiro Kojima, Reiko Kanuma, Daichi Takizawa, Toshiyuki Okumura, Hideyuki Sakurai, Hiroyuki Nishiyama
OBJECTIVE: We retrospectively elucidated the oncological outcomes, prognostic factors and toxicities of proton beam therapy in trimodal bladder-preserving therapy for muscle-invasive bladder cancer at our institution. METHODS: From 1990 to 2015, 70 patients with cT2-3N0M0 muscle-invasive bladder cancer underwent trimodal bladder-preserving therapy consisting of maximal transurethral resection of the bladder tumor, small pelvis photon irradiation, intra-arterial chemotherapy and proton beam therapy...
October 13, 2016: Japanese Journal of Clinical Oncology
Lu Han, Guo-Feng Zhang, Yue-Hu Cheng, Qi-Cheng Zhao
OBJECTIVE: This study is designed to evaluate the correlations of insulin-like growth factor I (IGF-I) and insulin-like growth factor I receptor (IGF-IR) expressions with the clinicopathological features and prognosis of patients with colon cancer. METHODS: From January 2010 to January 2009, tissue samples were collected from 121 colon cancer patients, 147 with colon adenoma and 63 patients with chronic diarrhea. Real-time quantitative polymerase chain reaction was used to analyze the mRNA expressions of IGF-I and IGF-IR...
October 13, 2016: Japanese Journal of Clinical Oncology
Koji Hatano, Takuya Okusa, Yu Ishizuya, Yasutomo Nakai, Masashi Nakayama, Ken-Ichi Kakimoto, Kazuo Nishimura
OBJECTIVE: To identify predictors for biochemical recurrence among patients with positive surgical margins (RM1) after radical prostatectomy and to examine the effect of ultrasensitive prostate-specific antigen measured early after prostatectomy on biochemical recurrence. METHODS: We identified 705 patients with prostate cancer who were treated with radical prostatectomy without preoperative hormonal therapy at our institution between 2000 and 2014. The patients with RM1 who had a postoperative prostate-specific antigen <0...
October 12, 2016: Japanese Journal of Clinical Oncology
Hidehito Horinouchi
A number of promising new approaches for both local and systemic control of locally advanced non-small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non-small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease...
October 4, 2016: Japanese Journal of Clinical Oncology
Lihong Cong, Shikun Wang, Teng Gao, Likuan Hu
OBJECTIVE: We want to review the value of 18-fluoro-deoxy-glucose positron emission tomography for response prediction of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy. METHODS: Studies were searched in Pubmed, Embase and Cochrane Library with specific search strategy. The published articles were included according to the criteria established in advance. The included studies were divided into two groups according to the time of the repeat positron emission tomography: during (Group A) or after neoadjuvant chemoradiotherapy (Group B)...
October 4, 2016: Japanese Journal of Clinical Oncology
Toshiyuki Seki, Hiroshi Tanabe, Chie Nagata, Jiro Suzuki, Kayo Suzuki, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Satoshi Takakura, Aikou Okamoto
OBJECTIVE: Patients with adeno/adenosquamous carcinoma may have a poorer prognosis than patients with squamous cell carcinoma. Radiotherapy and concurrent chemoradiotherapy are used as adjuvant therapies for cervical cancer, regardless of the histological subtype. The aim of this study was to investigate the prognostic outcome of adjuvant therapy for patients with adeno/adenosquamous carcinoma with pathological risk factors. METHODS: The medical records of 135 patients with stage IB-IIB cervical cancer with squamous cell carcinoma or adeno/adenosquamous carcinoma who underwent primary surgery followed by adjuvant therapy were retrospectively reviewed...
September 27, 2016: Japanese Journal of Clinical Oncology
Daniel K Ebner, Hiroshi Tsuji, Shigeo Yasuda, Naoyoshi Yamamoto, Shinichiro Mori, Tadashi Kamada
Phase-controlled rescanning of the carbon-ion beam offers fast and precise dose application with decreased irradiation of normal tissue. However, organ movement with respiration remains a unique challenge. Technological development has enabled the simultaneous application of beam-energy-modulated markerless phase-controlled rescanning with respiration gating, allowing scanning treatment of respiration-mobile tumors with carbon. A total of 10 patients with tumors in the liver or lung were treated in a feasibility study at our facility using this combination...
September 27, 2016: Japanese Journal of Clinical Oncology
Takeshi Shinozaki, Mitsuru Ebihara, Satoru Iwase, Takuhiro Yamaguchi, Hitoshi Hirakawa, Wataru Shimbashi, Tomoyuki Kamijo, Makito Okamoto, Takeshi Beppu, Junichiro Ohori, Kazuto Matsuura, Motoyuki Suzuki, Hiroshi Nishino, Yuichiro Sato, Hiroto Ishiki
BACKGROUND: Little is known about quality of life and functional status of patients with terminally ill head and neck cancers. METHODS: We conducted a multicenter, prospective, observational study to examine quality of life and functional status in terminally ill head and neck cancer patients. RESULTS: Of the 100 patients meeting inclusion criteria, 72 were observed until death. There was no significant difference in the quality of life score between baseline and Week 3...
September 27, 2016: Japanese Journal of Clinical Oncology
Ze-Xin Zhu, Ji-Wei Huang, Ming-Heng Liao, Yong Zeng
Hepatocellular carcinoma is the most common malignancy in liver, is also a global problem and is the fourth most commonly diagnosed cancers among men and the fourth leading causes of cancer death among both men and women in China. Liver resection or hepatic resection and radiofrequency ablation is widely accepted as a first-line surgical approach for hepatocellular carcinoma in China. However, the indications of radiofrequency ablation or hepatic resection are different and not unified in China. In this article, we review the current status of hepatic resection and radiofrequency ablation therapies in hepatocellular carcinoma management in China...
September 27, 2016: Japanese Journal of Clinical Oncology
Dong Wook Shin, Juhee Cho, So Young Kim, Hyung Kook Yang, BeLong Cho, Dong-Bok Shin, Mi Son Chun, Young Joo Min, Young-Woo Kim, Jong Hyock Park
OBJECTIVE: Phase I oncology trials have raised concerns that patients' 'unrealistic' optimism could compromise the validity of informed consent, and that patients often participate in trials to conform to physicians' or family members' recommendations. We aimed to determine whether patients or families-given the same information of risk-benefit profile-are more likely to participate in Phase I trials than their physicians and whether people in family or physician situations are more likely to recommend trial participation to patients than they would want for themselves as patients...
September 27, 2016: Japanese Journal of Clinical Oncology
Jun Kanamori, Keiju Aokage, Tomoyuki Hishida, Junji Yoshida, Masahiro Tsuboi, Takeo Fujita, Masato Nagino, Hiroyuki Daiko
OBJECTIVE: The purposes of this study were to determine the role of surgical treatment and to identify factors affecting survival of patients undergoing resection of pulmonary metastatic tumors from esophageal carcinoma. METHODS: We reviewed 33 patients who had undergone resection of pulmonary metastatic tumors from esophageal carcinoma after definitive treatment. RESULTS: The operative morbidity rate was only 5%, no patients died within 30 days after resection, and complete resection was achieved in 30 patients...
September 21, 2016: Japanese Journal of Clinical Oncology
Sho Takeshita, Yukiharu Todo, Hiroko Matsumiya, Kazuhira Okamoto, Katsushige Yamashiro, Hidenori Kato
OBJECTIVE: The aim of the study was to establish a predictive model of survival period after bone metastasis from endometrial cancer. METHODS: A total of 28 patients with bone metastasis from uterine corpus cancer were included in the study. Data at the time of bone metastasis diagnosis, which included presence of extraskeletal metastasis, performance status, history of any previous radiation/chemotherapy and the number of bone metastases, were collected. Survival data were analyzed using Kaplan-Meier methods and Cox proportional hazard models...
September 21, 2016: Japanese Journal of Clinical Oncology
Masayuki Ohue, Satoru Iwasa, Yukihide Kanemitsu, Tetsuya Hamaguchi, Manabu Shiozawa, Masaaki Ito, Masayoshi Yasui, Hiroshi Katayama, Junki Mizusawa, Yasuhiro Shimada
A randomized phase II/III trial was started in May 2015 comparing perioperative versus postoperative chemotherapy with modified infusional fluorouracil and folinic acid with oxaliplatin for lower rectal cancer patients with suspected lateral pelvic node metastasis. The standard arm is total mesorectal excision or tumor-specific mesorectal excision with lateral pelvic node dissection (LND) followed by postoperative chemotherapy (modified infusional fluorouracil and folinic acid with oxaliplatin; 12 cycles)...
September 21, 2016: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"